Chemotherapy News and Research

Latest Chemotherapy News and Research

Celgene receives FDA 'fast track' for Amrubicin in small cell lung cancer after first-line chemotherapy

Celgene Corporation today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Ondansetron helps reduce vomiting, hospital admissions in children with gastroenteritis

University of North Carolina at Chapel Hill researchers have demonstrated that a drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.

3 Sep 2008

Discovery of tumour growth enzyme could lead to new cancer drugs

Scientists say a landmark study has revealed an enzyme which is vital to the growth of many cancers.

1 Sep 2008

FDA grants IND for Davanat to treat breast cancer patient

Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.

28 Aug 2008

Takeda and Affymax provide update for Hematide in chemotherapy-induced anemia

Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.

28 Aug 2008

Some hospitals require insured patients to make larger upfront payments for elective procedures, surgeries

The South Florida Sun-Sentinel on Tuesday examined how across the U.S., "some insured patients are being asked by hospitals to pay larger portions of their bills upfront -- and sometimes hospitals will not do the procedures until they get their copayments."

28 Aug 2008

Protherics announces start of Prolarix phase 2 study in liver cancer

Protherics PLC today announced the initiation of a phase 2a proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treaent of primary liver cancer (hepatocellular carcinoma or "HCC"). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.

27 Aug 2008

Child's aggressive cancer spotted in a photo sent to a friend

A baby girl's photograph shown online to a friend of her mother has led to the child being diagnosed with a cancerous tumour.

27 Aug 2008

Normalizing tumor vessels to improve chemotherapy drug delivery

Chemotherapy drugs often never reach the tumors they're intended to treat, and radiation therapy is not always effective, because the blood vessels feeding the tumors are abnormal-"leaky and twisty" in the words of the late Judah Folkman, MD, founder of the Vascular Biology program at Children's Hospital Boston.

25 Aug 2008

OncoGenex Pharmaceuticals' OGX-011 granted FDA fast track status

OncoGenex Pharmaceuticals has announced that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive metastatic prostate cancer.

24 Aug 2008

New vaccine to fight multiple influenza strains

A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.

21 Aug 2008

Scientists engineer first drug-delivery particles capable of passing through human mucus

Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.

20 Aug 2008

Simple bowel cancer test spots deadliest tumours

British scientists say a simple bowel cancer test could save thousands of lives by spotting the deadliest tumours.

20 Aug 2008

Stanford develop method to overcome multiple drug resistant diseases

Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.

18 Aug 2008

New sickle cell unrelated transplant trial

Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.

18 Aug 2008